Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow

Phase 4 Completed 15 enrolled Allergan

RandomizedCrossoverDouble-blindTreatment

Summary

A 10 week evaluation, crossover design study including a 3 week washout period between treatments, to determine the effects of Combigan® (fixed combination brimonidine tartrate 0.2%/timolol maleate 0.5%) and Cosopt® (fixed combination dorzolamide hydrochloride-timolol maleate ophthalmic solutions) on ocular blood flow as measured by retrobulbar blood flow.

Timeline

Start: 2008-12
Primary completion: 2009-12
Completion: 2009-12

Publications

Background Siesky B, Harris A, Ehrlich R, Cantor L, Shoja MM, Rusia D, Hollander DA, Abrams L, Williams JM, Shoshani Y. Short-term effects of brimonidine/timolol and dorzolamide/timolol on ocular perfusion pressure and blood flow in glaucoma. Adv Ther. 2012 Jan;29(1):53-63. doi: 10.1007/s12325-011-0092-3. Epub 2012 Jan 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Brimonidine	Small molecule	0.2 %	Other
Comparator	Dorzolamide	Small molecule	—	Other
Comparator	Timolol	Other / unclassified	0.5 %	Other
Comparator	Timolol	Other / unclassified	—	Other

Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow

Summary

Timeline

Publications

Drugs

Indications